{"id":"https://openalex.org/W4402204017","doi":"https://doi.org/10.3389/fphar.2024.1396378","title":"Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS","display_name":"Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS","publication_year":2024,"publication_date":"2024-09-03","ids":{"openalex":"https://openalex.org/W4402204017","doi":"https://doi.org/10.3389/fphar.2024.1396378","pmid":"https://pubmed.ncbi.nlm.nih.gov/39290866"},"language":"en","primary_location":{"id":"doi:10.3389/fphar.2024.1396378","doi":"https://doi.org/10.3389/fphar.2024.1396378","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2024.1396378","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1396378/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1396378/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067143974","display_name":"Yuan Peng","orcid":"https://orcid.org/0000-0001-9563-9568","observed_orcids":["https://orcid.org/0000-0001-9563-9568"]},"institutions":[{"id":"https://openalex.org/I105086349","display_name":"North Sichuan Medical University","ror":"https://ror.org/05k3sdc46","country_code":"CN","type":"education","lineage":["https://openalex.org/I105086349"]},{"id":"https://openalex.org/I4210108565","display_name":"Affiliated Hospital of North Sichuan Medical College","ror":"https://ror.org/01673gn35","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210108565"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yuan Peng","raw_affiliation_strings":["Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China","School of Pharmacy, North Sichuan Medical College, Nanchong, Sichuan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China","institution_ids":["https://openalex.org/I4210108565"]},{"raw_affiliation_string":"School of Pharmacy, North Sichuan Medical College, Nanchong, Sichuan, China","institution_ids":["https://openalex.org/I105086349"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004112467","display_name":"Yuying Zhou","orcid":"https://orcid.org/0000-0003-4695-7169","observed_orcids":["https://orcid.org/0000-0003-4695-7169"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yuying Zhou","raw_affiliation_strings":["The First Clinical Medical College, Xuzhou Medical University, Xuzhou, Jiangsu, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The First Clinical Medical College, Xuzhou Medical University, Xuzhou, Jiangsu, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114220540","display_name":"Kaisen Shu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105086349","display_name":"North Sichuan Medical University","ror":"https://ror.org/05k3sdc46","country_code":"CN","type":"education","lineage":["https://openalex.org/I105086349"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Kaisen Shu","raw_affiliation_strings":["School of Pharmacy, North Sichuan Medical College, Nanchong, Sichuan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Pharmacy, North Sichuan Medical College, Nanchong, Sichuan, China","institution_ids":["https://openalex.org/I105086349"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100380897","display_name":"Jia Xu","orcid":"https://orcid.org/0000-0002-2444-8980","observed_orcids":["https://orcid.org/0000-0002-2444-8980"]},"institutions":[{"id":"https://openalex.org/I4210108565","display_name":"Affiliated Hospital of North Sichuan Medical College","ror":"https://ror.org/01673gn35","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210108565"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Xu Jia","raw_affiliation_strings":["Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China","institution_ids":["https://openalex.org/I4210108565"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5070368345","display_name":"Yan Zhong","orcid":"https://orcid.org/0000-0001-6344-3157","observed_orcids":["https://orcid.org/0000-0001-6344-3157"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Yan Zhong","raw_affiliation_strings":["Department of Pharmacy, Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region (Hospital.C.T), Chengdu, Sichuan, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region (Hospital.C.T), Chengdu, Sichuan, China","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5070368345"],"corresponding_institution_ids":[],"apc_list":{"value":3295,"currency":"USD","value_usd":3295},"apc_paid":{"value":3295,"currency":"USD","value_usd":3295},"fwci":4.5787,"has_fulltext":true,"cited_by_count":6,"citation_normalized_percentile":{"value":0.93566345,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":98},"biblio":{"volume":"15","issue":null,"first_page":"1396378","last_page":"1396378"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.0031999999191612005,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.9739999771118164},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9980000257492065},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.8650000095367432},{"id":"https://openalex.org/keywords/drug-safety-signals","display_name":"drug safety signals","score":0.6650000214576721},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9800000190734863},{"id":"https://openalex.org/keywords/carfilzomib","display_name":"carfilzomib","score":1.0},{"id":"https://openalex.org/keywords/ixazomib","display_name":"ixazomib","score":1.0},{"id":"https://openalex.org/keywords/fda-adverse-event-reporting-system","display_name":"FDA Adverse Event Reporting System","score":0.875},{"id":"https://openalex.org/keywords/reporting-odds-ratio","display_name":"reporting odds ratio","score":0.777999997138977},{"id":"https://openalex.org/keywords/bayesian-confidence-propagation-neural-network","display_name":"Bayesian confidence propagation neural network","score":0.9330000281333923},{"id":"https://openalex.org/keywords/infections-and-infestations","display_name":"infections and infestations","score":0.8600000143051147}],"concepts":[{"id":"https://openalex.org/C2777105317","wikidata":"https://www.wikidata.org/wiki/Q4686710","display_name":"Adverse Event Reporting System","level":3,"score":0.9665213823318481},{"id":"https://openalex.org/C2780108899","wikidata":"https://www.wikidata.org/wiki/Q15366934","display_name":"Carfilzomib","level":4,"score":0.8723548650741577},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8017374277114868},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.7114498615264893},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.693557858467102},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.5713777542114258},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5071473121643066},{"id":"https://openalex.org/C156957248","wikidata":"https://www.wikidata.org/wiki/Q1862216","display_name":"Odds ratio","level":2,"score":0.4849388897418976},{"id":"https://openalex.org/C151956035","wikidata":"https://www.wikidata.org/wiki/Q1132755","display_name":"Logistic regression","level":2,"score":0.41431671380996704},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.37047070264816284},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.32941681146621704}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.3389/fphar.2024.1396378","doi":"https://doi.org/10.3389/fphar.2024.1396378","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2024.1396378","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1396378/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},{"id":"pmid:39290866","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39290866","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in pharmacology","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:11405236","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11405236","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11405236/pdf/fphar-15-1396378.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Front Pharmacol","raw_type":"Text"},{"id":"pmh:oai:doaj.org/article:cf895cfe321341278426dd8ed678ccee","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/cf895cfe321341278426dd8ed678ccee","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Pharmacology, Vol 15 (2024)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fphar.2024.1396378","doi":"https://doi.org/10.3389/fphar.2024.1396378","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2024.1396378","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1396378/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9922999739646912,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.5600000023841858,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4402204017.pdf","grobid_xml":"https://content.openalex.org/works/W4402204017.grobid-xml"},"referenced_works_count":32,"referenced_works":["https://openalex.org/W1985864219","https://openalex.org/W1990836783","https://openalex.org/W2025579499","https://openalex.org/W2093676270","https://openalex.org/W2095514791","https://openalex.org/W2136735139","https://openalex.org/W2148120844","https://openalex.org/W2149479859","https://openalex.org/W2160088903","https://openalex.org/W2169183166","https://openalex.org/W2305515617","https://openalex.org/W2467918428","https://openalex.org/W2518238171","https://openalex.org/W2549396793","https://openalex.org/W2599636694","https://openalex.org/W2730396008","https://openalex.org/W2756923622","https://openalex.org/W2784250419","https://openalex.org/W2885850235","https://openalex.org/W2888120887","https://openalex.org/W2940739539","https://openalex.org/W2975911854","https://openalex.org/W2995557281","https://openalex.org/W3120885064","https://openalex.org/W3125503555","https://openalex.org/W3128240620","https://openalex.org/W3137633545","https://openalex.org/W3170989721","https://openalex.org/W3174394552","https://openalex.org/W4285498552","https://openalex.org/W4388638303","https://openalex.org/W4391651676"],"related_works":["https://openalex.org/W1850271161","https://openalex.org/W2592226531","https://openalex.org/W2394791231","https://openalex.org/W4394686056","https://openalex.org/W2066699439","https://openalex.org/W2987448391","https://openalex.org/W2611356063","https://openalex.org/W4210810123","https://openalex.org/W2061032583","https://openalex.org/W2063424779"],"abstract_inverted_index":{"Objective:":[0],"To":[1],"mine":[2],"and":[3,68,86,99,105,138,157,176,180,184,186],"analyze":[4],"adverse":[5,160],"events":[6],"(AEs)":[7],"related":[8,33],"to":[9,34,50,119],"proteasome":[10,37,201],"inhibitors":[11,38,202],"in":[12,126,129,210,219],"multiple":[13,35,199],"myeloma":[14,36,200],"based":[15],"on":[16],"the":[17,42,45,51,63,115,131,148,162,167,197],"FDA":[18],"Adverse":[19],"Event":[20],"Reporting":[21],"System":[22,107],"(FAERS),":[23],"providing":[24],"references":[25],"for":[26,81,84,88,114,196],"rational":[27],"clinical":[28,220],"medication.":[29],"Methods:":[30],"AE":[31,94,212],"data":[32],"were":[39,90,124,135,174,207],"collected":[40],"from":[41,44],"FAERS":[43],"first":[46,52],"quarter":[47,53],"of":[48,54,58,78,96,133,146,152,194],"2010":[49],"2024.":[55],"Signal":[56],"mining":[57],"AEs":[59,140,195],"was":[60,166,203],"conducted":[61],"using":[62],"reporting":[64,164],"odds":[65],"ratio":[66],"method":[67],"Bayesian":[69],"confidence":[70],"propagation":[71],"neural":[72],"network":[73],"method.":[74],"Results:":[75],"A":[76],"total":[77],"8,805":[79],"reports":[80],"bortezomib,":[82],"5,264":[83],"carfilzomib,":[85],"8,771":[87],"ixazomib":[89],"collected,":[91],"with":[92],"corresponding":[93],"signals":[95],"474,":[97],"279,":[98],"287,":[100],"respectively,":[101],"involving":[102],"23,":[103],"21,":[104],"22":[106],"Organ":[108],"Classes":[109],"(SOCs).":[110],"The":[111,170,191],"report":[112],"information":[113],"three":[116,198],"drugs":[117],"tended":[118],"be":[120,217],"consistent:":[121],"more":[122],"cases":[123],"reported":[125],"males":[127],"than":[128],"females;":[130],"majority":[132],"patients":[134],"65":[136],"years":[137],"over;":[139],"mostly":[141],"occurred":[142],"within":[143],"6":[144],"months":[145],"medication;":[147],"outcomes":[149],"primarily":[150],"consisted":[151],"hospitalization,":[153],"prolonged":[154],"hospital":[155],"stay,":[156],"other":[158],"serious":[159],"events;":[161],"primary":[163],"country":[165],"United":[168],"States.":[169],"most":[171],"affected":[172],"SOCs":[173],"infections":[175],"infestations,":[177],"general":[178],"disorders":[179],"administration":[181],"site":[182],"conditions,":[183],"blood":[185],"lymphatic":[187],"system":[188],"disorders.":[189],"Conclusion:":[190],"overall":[192],"distribution":[193],"consistent,":[204],"but":[205],"there":[206],"certain":[208],"differences":[209],"specific":[211],"signal":[213],"characteristics,":[214],"which":[215],"should":[216],"noted":[218],"applications.":[221]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":4}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2025-10-10T00:00:00"}